felzartamab

Home
Ligands
felzartamab

GtoPdb Ligand ID: 13455

Synonyms: MOR-03087 | MOR-202 | MOR03087 | MOR202

Comment: Felzartamab (MOR03087; MOR202) is a humanized anti-CD38 monoclonal antibody. It has immunosuppressive action and induces Fc-effector function. Anti-CD38 monoclonals are intended to target long-lived CD38⁺ autoantibody-secreting plasma cells and plasmablasts that persist in inflamed tissue and bone marrow niches, to mediate immunosuppression.

References
1. Caravaca-Fontán F, Yandian F, Fervenza FC. (2023) Future landscape for the management of membranous nephropathy. Clin Kidney J, 16 (8): 1228-1238. [PMID:37529655]
2. Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S et al.. (2022) Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials, 23 (1): 270. [PMID:35395951]
3. Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F et al.. (2024) A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection. N Engl J Med, 391 (2): 122-132. [PMID:38804514]

References

1. Caravaca-Fontán F, Yandian F, Fervenza FC. (2023)
Future landscape for the management of membranous nephropathy.
Clin Kidney J, 16 (8): 1228-1238. [PMID:37529655]

2. Mayer KA, Budde K, Halloran PF, Doberer K, Rostaing L, Eskandary F, Christamentl A, Wahrmann M, Regele H, Schranz S et al.. (2022)
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial.
Trials, 23 (1): 270. [PMID:35395951]

3. Mayer KA, Schrezenmeier E, Diebold M, Halloran PF, Schatzl M, Schranz S, Haindl S, Kasbohm S, Kainz A, Eskandary F et al.. (2024)
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
N Engl J Med, 391 (2): 122-132. [PMID:38804514]